Comparative Pharmacology
Head-to-head clinical analysis: HISTAFED versus OPTIMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HISTAFED versus OPTIMINE.
HISTAFED vs OPTIMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HISTAFED is a combination of pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa causing vasoconstriction, and triprolidine, a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby preventing histamine-mediated effects.
OPTIMINE (azathioprine) is a purine analog that inhibits DNA and RNA synthesis by interfering with purine metabolism. It is metabolized to 6-mercaptopurine, which inhibits de novo purine synthesis and suppresses T-lymphocyte proliferation.
60 mg orally every 4 to 6 hours as needed; maximum 360 mg per day.
1 mg orally twice daily; maximum 4 mg/day.
None Documented
None Documented
3-4 hours for pseudoephedrine component; shorter in children (2-3 h), prolonged in renal impairment
Terminal elimination half-life of 12-15 hours in healthy adults, prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal (approximately 65% as unchanged drug and metabolites), biliary/fecal (35%)
Renal: 65-75% as unchanged drug; biliary/fecal: 20-30% as metabolites; minor hepatic metabolism via CYP3A4.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine